Previous awards

The Centre’s unique scheme to provide pump-priming funds to support collaborative projects in cancer research has been a key area of activity. The scheme has proved an exceptionally useful tool in supporting the development of the Centre, and bringing the research community together.

Over the years the Centre has awarded over £2.3m across 170 projects and 185 principle investigators. Though still in its early stages, this investment has already yielded over £15 million in external grant funding, more than 80 publications, presentations or manuscripts, and seeded nearly 160 new collaborations nationally and internationally.

Previous Development Fund recipients are highlighted below:

February 2021

Tom Agnew, Sir William Dunn School of Pathology

ARH3 as a potential new biomarker in breast, ovarian and pancreatic and prostate cancer

Elizabeth Mann et al., The Kennedy Institute of Rheumatology, NDORMS

Ex vivo phenotyping of Th17 cells from colorectal cancer patients

Kourosh Honarmand Ebrahimi & James McCullagh, Department of Chemistry, Chemistry Research Laboratory

Metabolomics investigation of an emerging immunometabolic pathway linking viral infection and inflammation to cancer

Linna Zhou, The Ludwig Institute & Department of Chemistry

Engineered gastrointestinal tissues to investigate the influence of enteric neurons in cancer progression

Mariolina Salio & Graham Collins, Human Immunology Unit & Department of Haematology, Oxford University Hospitals

Immune microenvironment signatures predictive of response in patients with classical Hodgkin Lymphoma treated with checkpoint inhibitors

Karthik Ramasamy & Ross Sadler, Department of Haematology, Oxford University Hospitals & Nuffield Department of Medicine

Post translational modification of free light chains as a biomarker for progression from monoclonal gammopathy of undetermined significance to myeloma

Monica Olcina et al., MRC Oxford Institute for Radiation Oncology, Department of Oncology

C5aR1 as a biomarker in ovarian cancer – Towards the development of radioligands for imaging and therapy of C5aR1 expressing tumours

Ricardo Fernandes, Nuffield Department of Medicine

Development of a new approach to target FLT3 signalling in AML

Simon Carr & Wojciech Barczak, Department of Oncology

Tumour specific neo-antigens derived from the non-coding genome

Andrew Blackford, Department of Oncology

Characterising short linear peptide motifs in tumour suppressor proteins

Thomas Lanyon-Hogg, Department of Pharmacology

Development of novel Hedgehog acyltransferase inhibitors from HTS hits to lead series

Val Macaulay, Ian Mills & Jack Mills, Department of Oncology & Nuffield Department of Surgical Sciences

Investigating nuclear IGF-1R function in clinical prostate cancers

Wayne Paes et al., Centre for Cellular and Molecular Physiology, Nuffield Department of Medicine

Empirical determination of molecular biomarkers for precision-based immunotherapy in colorectal cancer

Shijie Cai et al., Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine

Identification of small molecule inhibitors and synthetic lethality for GTP cyclohydrolase in triple-negative breast cancer

June 2020

Ms Marketa Tomkova & Mr Michael McClellan Ludwig Cancer Research

Detection of non-clonal mutations and mutational signatures by single-molecule sequencing

Ms Yurena Vivas-García Ludwig Institute for Cancer Research, Nuffield Department of Medicine

Identification of pathways driving resistance to drugs targeting fatty acid saturation in cancer

Prof Simon Leedham & Ms Nadia Nasreddin Nuffield Department of Medicine

The WNT signalling pathway landscape of colitis-associated colorectal cancer

Ms Mara Artibani Nuffield Department of Women’s and Reproductive Health / Weatherall Institute of Molecular Medicine

Establishing a 3D model of minimal residual disease for drug screening

Prof Matthew Freeman Sir Dunn School of Pathology

Developing animal models of iRhom2, a potential new target in KRAS-induced cancer

Dr Lonnie Swift Department of Oncology

Exploiting synthetic defects in metabolism and DNA repair to improve the treatment of glioma

Prof Geoff Higgins Department of Oncology

Preclinical evaluation of Atovaquone as an immune therapy sensitiser

Prof Richard Gibbons Radcliffe Department of Medicine /Nuffield Division of Clinical Laboratory Sciences /WIMM Weatherall Institute of Molecular Medicine

Genome-wide optical mapping of replication stalling

Ms Ysobel Baker & Prof Tom Brown Department of Chemistry

New chemical architectures for the therapeutic targeting of RNA

Dr Benjamin Fairfax Department of Oncology

Characterising the cfDNA methylome in patients with metastatic melanoma treated with immune checkpoint blockade

January 2019

Dr Lynn Quek, MRC MHU, Weatherall Institute of Molecular Medicine

Single cell transcriptomic and proteomic analysis of granulocyte-monocyte and erythroid differentiation in normal haematopoietic progenitors and in Acute Myeloid Leukaemia.

Dr Gillian Farnie, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences

Investigating tumour heterogeneity to discover mechanisms of inherent and therapy induced resistance

Prof. Anne Kiltie, CRUK/MRC Oxford Institute of Radiation Oncology

Development of a human gastrointestinal epithelial organoid assay to identify non-toxic chemoradiation combinations for abdominal and pelvic tumours

Dr Shivan Sivakumar, Department of Oncology

Mapping the T cell architecture of pancreatic cancer

Dr Natalia Gromak, Sir William Dunn School of Pathology

Molecular Mechanism of APOBEC3B-Dependent targeting of pathological R loops in breast cancer

Dr Benjamin Schuester-Bockler, Nuffield Department of Medicine, Big Data Institute 

Determining the mechanism of mutagenesis in gastric and oesophageal adenocarcinomas

Dr Jacqueline Boultwood, Nuffield Division of Clinical Laboratory Sciences

Single-cell analysis of haematopoietic stem cells in advanced myelodysplastic syndromes: identification of new therapeutic treatments/targets

Dr Jordan Becker, Wellcome Centre for Human Genetics 

Dissecting the mechanism of BRCA1-BARD1 complex function in DNA double-strand break repair

Dr Jan Bornschein, Translational Gastroenterology Unit

Transcriptome profiling of different stages of inflammatory, preneoplastic, and neoplastic alterations of the gastric mucosa by RNA-sequencing. Analysis of risk-factor associated gene expression signatures and virtual microdissection to enable analysis of epithelial-stromal interaction.

Dr Fumiko Esahi, Sir William Dunn School of Pathology

Exploring the role of BRCA1 AND PALB2 in myeloid differentiation

Prof Sarah Blagden, Department of Oncology

The Role of Olaparib and PARPs in the Cellular Stress Response

Dr Jakub Kopycinski, Nuffield Department of Medicine

Use of High-Definition immune profiling to understand mechanisms underpinning control of high-risk Human Papillomavirus (hrHPV) in exposed women.

Dr Dawn O’Reilly, Department of Oncology

Examine the feasibility of long-range sequencers to build a comprehensive transcriptome isoform blueprint of human breast cancer cells– “a proof of concept” study.

Dr Michael Tellier, Sir William Dunn School of Pathology

Understanding the function of the cyclin-dependent kinase 10 (CDK10) and cyclin M (CycM) in cancer and STAR syndrome, a developmental genetic disease

Prof Ahmed Ahmed, Nuffield Department of Women’s & Reproductive Health

Molecular validation of a putative novel aggressive molecular subtype of ovarian cancer

March 2018

Brian Lyons, Department of Oncology
Use of a mirror image D-amino acid peptide shield to induce immune silencing of an oncolytic virus rendering it hidden to pre-existing neutralising antibodies thus increasing bio-availability and therapeutic efficacy

Abirami Lakshminarayanan, Radiobiology Research Institute, Department of Oncology
Antibody fragments as next generation imaging probes for radiation therapy

Felix Clanchy, Kennedy Institute of Rheumatology
How do IRAK-3 Isoforms contribute to tumour progression?

Akane Kawamura, Department of Chemistry
Targeting the NSD family protein methyltransferases for cancer treatment

Lisa Heather, Department of Physiology, Anatomy and Genetics
Fatty acids as novel metabolic regulators of HIF signalling and hypoxic sensitivity in cancer

Fiona Bangs, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology and The Kennedy Institute of Rheumatology
The impact of the primary cilium on initiation and progression of pancreatic ductal adenocarcinoma

Serena Lucotti, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology
Targeting tumour cell transendothelial migration during metastasis

Richard Bryant, Nuffield Department of Surgical Sciences
Transcriptomics of pre-radiotherapy prostate cancer biopsy samples – a “proof-of-concept” study

Audrey Gerard, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and The Kennedy Institute of Rheumatology
Increasing cancer vaccine efficacy through temporal blockade of IFNg

Peter Holland, Department of Zoology
Assessment of novel Testicular Germ Cell Tumour markers

Adam Cribbs, Botnar Research Centre – Oxford Centre for Translational Myeloma Research
Identifying epigenetic targets to modulate immune checkpoints in the treatment of multiple myeloma

Tim Humphrey, CRUK-MRC Oxford Institute for Radiation Oncology, Department of Oncology
Binding partners and imaging of the p53-targeting agent RITA

Simon Aldridge, Department of Chemistry
Novel boron-containing 18F tags for PET and bimodal imaging

Hagen Schwenzer, Department of Oncology
Exploring LARP6 as new potential drug target to treat HER2-negative gastric cancer

July 2017

Dr Viktor H. Koelzer, Wellcome Trust Centre for Human Genetics
Prof Tim Maughan, CRUK/MRC Oxford Institute for Radiation Oncology
Expression and polymorphisms of the pattern recognition receptors Stimulator of Interferon Genes (STING) and Toll-like Receptor (TLR) 4 as predictors of disease free survival in the Short Course Oncology Treatment (SCOT) trial of stage II-III colorectal cancer patients.

Mr Puneet Plaha, Oxford University Hospitals NHS Foundation Trust
Mr James Livermore, Department of Neurosurgery
Using night vision goggles to increase the precision of brain tumour surgery

Dr Bart Cornelissen, Department of Oncology
Peptide radionuclide imaging and therapy for pancreatic neuroendocrine tumours

Dr Heidi Olzscha, Department of Oncology
Characterisation of the citrullinome in malignant cell model systems

Dr Alvina G Lai, Professor Jane A McKeating, Target Discovery Institute, Nuffield Department of Medicine
Hypoxic-gene signatures in hepatitis B virus infection that predict hepatocellular carcinoma progression

Dr Vincenzo D’Angiolella, Department of Oncology
A system wide approach to investigate the role of deoxyribonucleotides (dNTPs) in genome stability and cancer cell survival

Dr Richard Owen, Ludwig Cancer Research
An integrative analysis of genomic, proteomic and histology image features in oesophageal metaplasia, dysplasia, and adenocarcinoma.

Dr Enric Domingo, Department of Oncology
Assessment of formalin-fixed paraffin embedded DNA for genome-wide associations studies

Dr Joshua W Owen, IBME
The development of oxygen loaded nanodroplets designed to deliver oxygen under the application of ultrasound for the treatment of tumour hypoxia.

Dr Ole Tietz, Department of Oncology
Intracellular targeting of cancer testis antigens (CTAs) using multimeric cell penetrating peptide (CPPs) clusters

January 2017

Dr John Jacob, Clinical Neuroscience
Dr Vincenzo D’Angiolella, Dr Frances Willenbrock, Oncology
Resolving the significance and mechanism of altered cholesterol metabolism in sonic hedgehog driven medulloblastoma

Prof Catherine Green, WTCHG
SetD3 as a novel target for cancer therapeutics

Prof Alison Banham, NDCLS
Dr Daniel Ebner, TDI
CRISPR Whole Genome Screen to Identify Pathways Driving Expression of the FOXP1 Oncogene

Dr Jia-Ling Ruan, Prof Anne Kiltie, Oncology
Immunomodulation by Gemcitabine-Based Chemoradiation Therapy in Muscle Invasive Bladder Cancer

Prof Simon Leedham, WTCHG
Using somatic mutation to reflect variable underlying disease pathogenesis in colorectal cancer

Dr Imre Mäger, DPAG
The proteome and brain microvascular endothelial cell interactions of brain-metastatic breast cancer extracellular vesicles

Prof Shona Murphy, Dr Justyna Zaborowska, Dunn School
CDK12 at the front line of the DNA Damage Response

Dr Bart Cornelissen, Oncology
Discovery of novel targets to image the effects of irradiation

Dr Gillian Farnie, NDORMS
Prof Claire Edwards, NDS
The influence of bone marrow adipocytes on the activity and dormancy of breast cancer metastasis

Dr Jurgen Brem, Chemistry
Dynamic combinatoria chemistry to develop novel anticancer agents

Prof Panagis Filippakopoulos, SGC
Prof Eric O’Neil, Oncology
Prof Tom Milne, Wimm
BRD4-directed recruitment of NuRD as a potential therapeutic target in cancer

Dr Johanna Michl, Prof Madalena Tarsounas, Oncology
Developing inhibitors of the Fanconi anemia pathway for the treatment of BRCA1/2-deficient cancers

Prof Adam Mead, WIMM
Measuring DNA Damage in Single Cells Using a Novel High Throughput Genomic Assay

Dr Nick Coupe, Oncology
In Vivo investigation of the orphan receptor ROR2 in angiogenesis and bevacizumab sensitivity in BRAF mutant melanoma

Dr Alfredo Castello Palomares, Biochemistry
Decoding the role of the RNA binding activity of p53

Prof Ian Tomlinson, Dr Lennard Lee, WTCHG
Colorectal cancer metastasis signatures and immune profiling of the lymphoid niche – predicting tumour recurrence

Dr Nicola Farrer, Chemistry
Ultrasonic Delivery of Pt(IV) Prodrugs

Dr Annabelle Lewis, Dr Roland Arnold, WTCHG
Identification of drivers of colon cancer cell differentiation: using a validated genomewide CRISPR transcriptional activation screen.

Dr Yanyan Jiang, Dr Anderson Ryan, Oncology
Targeting DNA-PK to selectively potentiate radiosensitivity in a xenograft model of lung cancer by contextual synthetic lethality

Dr Bilyana Stoilova, Prof Paresh Vyas, MHU
Determining the heterogeneity of progenitor phenotypes in human Acute Myeloid Leukaemia

Prof Nicholas La Thangue, Dr Rebecca Miller, Oncology
Dr Weston Struwe, Glycobiology
Heparin sulfate oligosaccharides that bind and inhibit tumourigenic growth have potential as drugs to limit glioma progression

Dr Anjali Kusumbe, Kennedy
Regulation of breast cancer cell metastasis by distinct blood vessel subtypes in the bone marrow microenvironment

Dr Tom McAllister, Dr Akane Kawamura, Chemistry
Cyclic Peptides inhibitors of the IGF/IGF-1R Interaction

Prof Ahmed Ahmed, NDOG
Targeting FER for the treatment of ovarian cancer

June 2016

Prof Kristijan Ramadan, Department of Oncology
Characterization of the SPRTN metalloprotease in DNA-protein crosslinks repair and its potential for cancer therapy

Dr Andrew Protheroe, OUH NHS Foundation Trust
Dr Kilian Huber,
Chemical proteomics to define the kinome of renal cancer and investigate resistance mechanisms to kinase inhibitors

Dr Victor Bolanos-Garcia, Oxford Brookes University
Prof Paul Brennan, SGC
New anticancer therapies through inhibitiion of Anaphase Promoting complex/cyclosome (APC/C) activation by Cdc20

Prof Paul Fairchild, Dunn School of Pathology
Exploiting the epigenetic memory of iPS cells to optimise dendritic cell based vaccinesNew anticancer therapies through inhibitiion of Anaphase Promoting complex/cyclosome (APC/C) activation by Cdc20

Dr Barbara Braden, OUH NHS Foundation Trust
Computer-aided recognition of Barrett’s oesophagus and its early neoplastic changes

Dr Thomas Ashton, Department of Oncology
Study of the anti-malarial, Atovaquone, as an anti-cancer therapeutic

Dr Dimitris Karamitros, MRC Molecular Hematology Unit
Implementation of novel xenotransplantation mouse models for study of human AML LSC

Dr Pavitra Kannan, Dr Benjamin Irving, Department of Oncology
Linking functional MRI with 3D microscopy to assess radiotherapy response in tumour subregions

Prof Deborah Goberdhan, DPAG
Prof Tudor Fulga, WIMM
Proteome and transcriptome of stress-induced cancer exosomes

Dr Ian Gibbs-Seymour, Dunn School of Pathology
Generation of tools to assess a potential new biomarker in breast, ovarian and prostate cancer tissues

Dr Jyothi Menon, Prof Kate Vallis, Department of Oncology
Prof Robert Carlisle, IBME
Ultrasound-responsive nanocomposite hydrogels for treatment of localised chest wall cancer recurrence

Dr Margaret Duffy, Prof Len Seymour, Department of Oncology
Establishing an ex vivo culture platform for slices from freshly-resected human tumours

Dr Jadwiga Nieminuszczy, Department of Oncology
Biochemical characterisation of a novel exonuclease required for homologous recombination as potential target for improving cancer therapy

January 2016

Prof Shoumo Bhattacharya, Cardiovascular Medicine
Targeting the chemokine system in breast and metastatic colon cancer using novel Evasins identified from tick saliva

Prof Colin Goding, Ludwig Cancer Research
Prof Sarah Blagden, Department of Oncology
Translation reprogramming as a therapeutic target in cancer

Dr Bart Cornelissen, Department of Oncology
Prof Veronique Gouverneur, Department of Chemistry
PET Imaging with PARP inhibitors

Dr Oleg Fedorov, Prof Paul Brennan, SGC
Prof Udo Oppermann, NDORMS
Towards development of histone methyl-lysine reader inhibitors for SPIN1- a novel molecular target in liposarcoma

Prof Udo Oppermann, NDORMS
Dr Karthik Ramasamy,  OUH NHS Foundation Trust
Tool development to monitor immune suppressive mechanisms by epigenetic inhibitors in multiple myeloma

Dr James Larkin, Prof Nicola Sibson, Department of Oncology
Metabolomic identification of melanoma and lung cancer patients with brain metastases

Dr Simon Lord, OUH NHS Foundation Trust
Dr Neel Patel, OUH NHS Foundation Trust
Dr Anderson Ryan, Department of Oncology
Repurposing cardiac perfusion imaging as a biomarker of anti-angiogenic and antimitochondrial therapy

Dr Benoit Van den Eynde, Ludwig Cancer Research
Developing viral vectored vaccines for MAGE-expressing tumours

Prof Nicholas Lakin, Department of Biochemistry
Identifying novel applications for the use of PARP inhibitors in cancer treatment

Prof Robert Gilbert, STRUBI
Prof Chris Norbury, Dunn School of Pathology
Prof Geoff Higgins, Department of Oncology
Development of improved inhibitors of cytoplasmic uridylyl transferases implicated in multiple types of cancer, including those of unmet need

Dr Eleftheria Dafni Pefani, Dr Eric O’Neill, Department of Oncology
Uncovering the crosstalk between RASSF1A and BLM to target cancer

Dr Yvonne Couch, RDM
Real-time electrical impedance assessment of barrier permeability responses to inflammatory mediators

Dr Catrine Johansson, Department of Chemistry
Structural and functional characterisation of the histone demethylase JMJD1C a potential therapeutic drug target in leukaemia

Dr Judith Nicholson, Prof Anne Kiltie, Department of Oncology
Mapping and validating clinically significant acetylation modifications in the DNA damage response pathway related to radiosensitisation mechanisms

Prof Stephen Faulkner, Department of Chemistry
Dr Bart Cornelissen, Dr Rebekka Hueting, Department of Oncology
Novel 89Zr chemistry for molecular imaging

Dr Lynn Quek, RDM
Lentiviral Barcoding of Primary Human AML Stem Cells

Dr Michael Holmes, Prof Zhenhming Chen, CTSU
Using novel metabolomics profiling for improved risk prediction and understanding of aetiology of pancreatic cancer

Dr Mariolina Salio, Prof Enzo Cerundolo, MRC Human Immunology Unit
Analysis of the T Cell repertoire in bladder cancer

Dr Ronan Broderick, Department of Oncology
Exploiting the potential on a novel human exonuclease required for homologous recombination in cancer therapy

Dr Richard Hopkinson, Department of Chemistry
Investigating the Molecular Mechanisms of Formaldehyde-induced Carcinogenicity

Prof Richard Gibbons, Dr Dennis Ptchelkine, WIMM
Determining the structure of the ATRX tumour suppressor complex

June 2015

Dr Omer Dushek, Sir William Dunn School of Pathology
Phenotypic models of chimeric antigen receptors for cancer therapy

Dr Tim Humphrey, CRUK / MRC Oxford Institute for Radiation Oncology
Determinants of histone H3K36Me3 loss and tumorigenesis

Dr Bostjan Markelc, CRUK / MRC Oxford Institute for Radiation Oncology
Understanding the blood flow and sprouting angiogenesis in tumours via a multidisciplinary approach based on mathematical modelling and 3D in vivo imaging

Dr Valentine Macaulay, Dr Tamara Aleksic, Department of Oncology
Investigating the clinical-translational significance of nuclear IGF-1R

Prof Peter McHugh, Department of Oncology
Prof Jan Rehwinkel, 
Weatherall Institute of Molecular Medicine
Prof Adrian Harris,
Department of Oncology
Investigating how the therapeutic DNA damage induces and antiviral state and the role of CDK8, a druggable kinase, in mediating this process

Dr James FranklinCRUK & EPSRC Cancer Imaging Centre in Oxford
Genomic characterisation of imaging phenotypes in colorectal liver metastases

Dr Fiona Larner, Department of Earth Sciences
High Precision Zinc Isotopic Compositions in Breast Cancer

Dr Michael McDonough, Department of Chemistry
Hypoxia-Inducible Factor-Independent Roles of the Major Kidney Tumour Suppressor von Hippel-Lindau Protein

Dr Clare Verrill, Nuffield Department of Surgical Sciences
Evolution of prostatic adenocarcinoma to neuroendocrine (small cell) carcinoma after hormonal or radiotherapy as a therapy resistance mechanism: a pilot next generation sequencing and immunohistochemical study

Dr Katarzyna Leszczynska, Prof Ester Hammond, CRUK / MRC Oxford Institute for Radiation Oncology
Investigation of hypoxia-regulated p53 function in cancer through its novel downstream target, LGR6

Dr Martin Cohn, Department of Biochemistry
The Fanconi Anemia FANCD2/FANCI protein complex as a potential therapeutic cancer target

Dr Whitney Kellett, Prof James McCullagh, Department of Chemistry
Supercritical fluid chromatography-mass spectrometry metabolomics of glioblastoma

Prof Panagis Filippakopoulos, Structural Genomics Consortium 
ZMYND8-regulation of MITF as potential therapeutic target in melanoma

Dr Eric O’Neill, Department of Oncology
Dr Szele, Department of Physiology, Anatomy & Genetics
Degregulation of Neuronal Stem Cells and Glioma Development

January 2015

Dr Samantha Hughes, Dr Aziz Aboobaker, & Dr Nobu Kosaka Department of Zoology
An Invertebrate Model to Investigate the Molecular Mechanisms Regarding Sensitivity to Radiation

Dr Roman Fischer & Dr Matthew Cockman, Nuffield Department of Clinical Medicine
Dr Sarah Larkin Nuffield Department of Clinical Neurosciences
Defining the Deep Hypoxia Proteome in Cancer – a Space & Tissue Resolved Case Study on Brain Tumours

Professor Michael Chappell Institute of Biomedical Engineering
DoxCEST:Non-invasive monitoring of targeted chemotherapeutic doxorubicin delivery using Chemical Exchange Saturation Transfer MRI

Dr Su Yin Lim & Professor Ruth Muschel CRUK / MRC Oxford Institute for Radiation Oncology
Angiopoietin-like protein 7 (ANGPTL7) expression in colorectal cancer liver metastasis

Dr Sarah Wordsworth & Dr Paul Hewitson Nuffield Department of Population Health
Could adding genetics to the Bowel Cancer Screening Programme be an acceptable and cost-effective option for the NHS?

Professor Fiona Powrie, Ms Sarah McCuaig, Dr Nathan West Kennedy Institute
Professor Tim Maughan Department of Oncology
IL-22 signalling and KRAS mutation synergize to promote malignancy and poor prognosis in colorectal cancer

Dr Madalena Tarsounas CRUK / MRC Oxford Institute for Radiation Oncology
Targetting BRCA2 deficiency with GSK3 inhibitors

June 2014

Dr Akane Kawamura & Dr Christoph Loenarz, Department of Chemistry
TET inhibitors: probes for DNA modifications in oncology

Dr Anderson Ryan, Department of Oncology
In vivo whole genome shRNA screen to identify novel targets for radiosensitisation

Dr Brian Marsden & Mr Michael O’Hagen, Structural Genomics Consortium
Exploring the breadth of chemical biology at Oxford: a symposium by ChemBio Hub to strengthen interdepartmental research connections

Dr Chris Yau, Wellcome Trust Centre for Human Genetics
Statistical methods for integrating single-cell RNA sequencing with single-cell imaging analysis for the study of cancer therapy resistant stem cells

Dr Irina Redchenko, The Jenner Institute 
Pre-clinical efficacy evaluation of the vectored vaccine with PD1 monoclonal antibody as a combination immunotherapy for prostate cancer

Dr Ross Chapman, Wellcome Trust Centre for Human Genetics 
Molecular characterisation of a novel function of the 53BP1 protein in tumour suppression

Dr Kristijan Ramadan & Dr Ignacio Torrecilla, Department of Oncology 
Dynamics of p97/VCP interactome after ionizing radiation

Dr Lucy Dorrell, Nuffield Department of Medicine
Development of novel viral vectored multi-genotype vaccines for therapy of human papillomavirus infections (HPV).

Dr Panagis Filippakopoulos, Structural Genomics Consortium
Professor Sir Walter Bodmer & Professor Tim Maughan, Department of Oncology
Role of bromo and extra-terminal (BET) proteins in colorectal cancer

January 2014

Professor Adrian Harris, Dr Alan McIntyre, Dr Daniel Ebner & Dr Geoff Higgins, Department of Oncology 
The epigenetics of breast cancer and response to hypoxia

Dr Bart Cornelissen & Dr Somnath Mukherjee, Department of Oncology
Molecular imaging biomarkers of gemcitabine resistance in advanced mouse models of pancreatic adenocarcinoma

Dr Benjamin Fairfax, Wellcome Trust Centre for Human Genetics 
Investigating human variation in ATM expression, functional outcomes and relationship to Metformin response

Professor Colin Goding, Ludwig Cancer Research
Professor Mark Middleton, Department of Oncology
Generating melanoma-initiating cells and pre-clinical testing a novel anti-melanoma agent

Dr Ester Hammond & Dr Somnath Mukherjee, Department of Oncology
Preclinical testing of novel therapy combinations for oesophageal cancer

Professor Katherine Vallis, Department of Oncology
Dr Sonia Trigueros, Department of Physics
The Application of Nanotechnology to Oncology: The Smart NanoSystem

Dr Svetlana Khoronenkova, Department of Oncology
X-­‐linked mental retardation syndrome: deficiency in the DNA damage response

Dr Simon Leedham, Wellcome Trust Centre for Human Genetics 
Clonal diversity as a biomarker of cancer progression in resected colorectal polyps

Professor Vincenzo Cerundolo & Dr Simon Davis, Radcliffe Department of Medicine
Professor Mark Middleton,
Department of Oncology
Professor Tim Maughan, CRUK MRC Oxford Institute for Radiation Oncology
Combined use of radiotherapy and PD1 blocking antibodies to enhance tumour specific immune responses

June 2013

Dr Anne Kiltie, CRUK MRC Oxford Institute for Radiation Oncology
Pre-clinical testing of panobinostat as a radiosensitising agent in bladder cancer

Dr Adam Mead, Nuffield Division of Clinical Laboratory Sciences 
Unravelling clonal complexity in myelofibrosis stem cells though application of single cell transcriptomics

Dr David N Church, Department of Oncology
Pilot evaluation of digital PCR and tagged amplicon sequencing to assess circulating tumour DNA in patients with metastatic melanoma and colorectal cancer

Dr Daniel Whalen, Dr Claire Palles & Professor Ian Tomlinson, Nuffield Department of Medicine 
Structural and biochemical characterisation of human DNA polymerase epsilon and cancer-‐associated variants

Dr Geoff Higgins, Dr Nick de Pennington & Dr Nicola Sibson, Department of Oncology 
Development of primary cell culture facilities in neuro-oncology

Dr Peter McHugh & Professor Adrian Harris, Department of Oncology 
Specific killing of Fanconi anemia deficient Cancer cells with a Cdk inhibitor – a preclinical analysis prior to phase I development

Dr Tim Humphrey & Dr Anderson Ryan, CRUK MRC Oxford Institute for Radiation Oncology
Preclinical validation of a breakthrough therapy for SETD2-deficient cancers

Dr Tatjana Sauka-Spengler, Radcliffe Department of Medicine 
Developing a zebrafish model for regulatory profiling of cancer cell subpopulations

Dr Vincenzo D’Angiolella, Department of Oncology 
Regulation of dNTP pools homeostasis during the DNA damage response

January 2013

Dr Anne Kiltie, CRUK MRC Oxford Institute for Radiation Oncology
Radiosensitising effects of histone deacetylase inhibitors: preclinical biomarker development in bladder cancer

Dr Eric O’Neill & Dr Simon Scrace, CRUK MRC Oxford Institute for Radiation Oncology
Personalised therapeutic targeting of tumours

Dr Francisco Perez-Balderas & Dr Nicola Sibson, Department of Oncology 
Targeting angiogenesis: novel particulate systems for advanced treatment of cancer

Dr Martin Cohn, Department of Biochemistry 
Characterization of novel FANCD2-­‐interacting proteins

Dr Patrick John Pollard, Nuffield Department of Medicine 
A Functional Genetic Screen in a Novel Model of Fumarate Hydratase Deficiency

Dr Ricky Sharma, Department of Oncology 
Discovery of drugs to sensitise cancer cells and hepatic stellate cells to radiotherapy

Dr Sébastien Serres, CRUK MRC Oxford Institute for Radiation Oncology 
Development of quantitative pH‐imaging to study tumour microenvironment in Medulloblastoma

Dr Remko Prevo & Dr Geoff Higgins, Department of Oncology 
A compound screen to identify novel sensitisers for radiation and platinum treatment in lung cancer

June 2012

Dr Alex Bullock & Dr Georgina Kerr, Structural Genomics Consortium 
New strategies to circumvent resistance to VEGF inhibition in tumour angiogenesis

Dr Benjamin Fairfax, Wellcome Trust Centre for Human Genetics 
Mutation detection in circulating DNA to assess disease burden and progression in Renal Cell Carcinoma

Dr Deborah Goberdhan & Dr Clive Wilson, Department of Physiology, Anatomy and Genetics
Dr Claire Edwards & Dr James Edwards, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
Professor Adrian Harris, Department of Oncology
Professor Ian Sargent, Nuffield Department of Obstetrics & Gynaecology
Professor Freddie Hamdy, Nuffield Department of Surgical Sciences 
Dissecting the Regulation and Functions of Tumour Cell Exosomes

Professor David Vaux, Sir William Dunn School of Pathology
Dependence of the mutation burden in mitochondrial DNA on the expression of functional BRCA1

Dr Emily Flashman, Department of Chemistry 
Histone Demethylase Activity in Hypoxia

Dr Holm Uhlig, Experimental Medicine Division
Immune dysregulation in patients with PTEN hamartoma tumor syndrome

Professor Sir Michael Brady, Department of Oncology 
Biomechanics and Elastography of breast tumours

Dr Nadia Falzone, Department of Oncology 
Development of robust experimental models to evaluate the effect of heterogeneous distribution of targeted radiotherapeutics

Dr Naomi Sharma & Professor Freddie Hamdy, Nuffield Department of Surgical Sciences
Dr Anne Kiltie, CRUK MRC Oxford Institute for Radiation Oncology  
Novel pre-clinical models and imaging techniques in urological malignancies

Dr Stephen Kearsey, Department of Zoology
Using laser ablation to study recruitment of repair factors to sites of DNA damage

Dr Svetlana Khoronenkova, Department of Oncology
Role of the E3 ubiquitin ligase Mule in the DNA damage response: links to carcinogenesis sites of DNA damage

Dr Simon Leedham & Professor Ian Tomlinson, Wellcome Trust Centre for Human Genetics 
Use of Next-Generation Sequencing to Investigate the Evolution Of Sub-Clones Within Colorectal Tumours

Dr Valentine Macaulay, Department of Oncology
Dr Gareth Bond, Nuffield Department of MedicineLudwig Cancer Research
The evaluation of IGF-1R as a biomarker for treatment response to DNA damaging cancer therapies

Professor Xin Lu, Ludwig Cancer Research
Dr Olaf Ansorge, Department of Neuropathology and Ocular Pathology
Investigating a potential role of the ASPP proteins in anti-EGFR mediated cancer therapy: Molecular characterisation of the Oxford Glioma Cohort

Dr Gareth Bond & Professor Ian Tomlinson, Nuffield Department of Medicine / Ludwig Cancer Research
Transcriptional control of p21 and its relationship to colorectal cancer susceptibility

January 2012

Dr Aaron Leiblich, Nuffield Department of Surgical Sciences
Dissecting the Complex Biology of Prostate Cancer Cells Using the Novel Drosophila Accessory Gland Model

Dr David N Church, Department of Oncology
Mechanistic and biomarker evaluation of FBW7 mutation in colorectal and endometrial cancers

Dr Helen Townley, Department of Engineering Science 
Spectrofluorometer to monitor both powders and liquid samples

Dr James McCullagh, Department of Chemistry 
Towards Isotopic Biomarkers for Cancer: A novel application

Dr Norma Masson, Nuffield Department of Medicine 
Assessment of the role of BPGM in cancer cell metabolism

Dr Philip Simister & Dr Stephan Feller, Weatherall Institute of Molecular Medicine 
Targeting an ‘Achilles heel’ in the molecular signal computation of cancer cells

Dr Simon Leedham, Wellcome Trust Centre for Human Genetics 
Investigating the mechanism and consequences of derangement of tissue-specific GREMLIN1 expression in familial and sporadic colorectal carcinogenesis

June 2011

Dr Gareth Bond, Nuffield Department of Medicine / Ludwig Cancer Research 
The identification and characterisation of single nucleotide polymorphisms (SNPs) in 14-3-3tau and CD44 that affect human cancer

Dr Nadia Falzone, Department of Oncology 
Demonstration of nano-scale 3-D visualization of dose patterns from radionuclides used for targeted cancer therapeutics using chemically enhanced resists

Dr John Fox, Department of Engineering Science
Advanced information technology to support decision-making in the breast cancer multi-disciplinary meeting

Dr Deborah Goberdhan, Department of Physiology, Anatomy and Genetics 
Characterisation of Proton-Assisted Amino Acid (PAT/SLC36) Transporter Function in Cellular Resistance to Microenvironmental Stress During Tumorigenesis

Dr Eric O’Neill, CRUK MRC Oxford Institute for Radiation Oncology
Analysis of SNPs in tumour suppressor regulatory genes that affect outcome in the COIN trial.

Dr Milap Rughani, Department of Oncology
Inhibition of the Phosphatidylinositol-3 Kinase pathway in melanoma cells in relation to senescence

Dr Pamela Sivathondan, Nuffield Department of Surgical Sciences / Nuffield Department of Obstetrics and Gynaecology
The development of a 3D primary human hepatocyte and liver stem cell culture system to study hepatocyte dysfunction and strategies for resuscitation in vitro

Dr Pawel Swietach, Department of Physiology, Anatomy and Genetics
Implementing a high‐throughout assay to measure intracellular and membrane‐bound carbonic anhydrase activity in cancer cells

Mr Stuart Winter, Ear, Nose and Throat 
Dr Stephan Feller, Department of Oncology
High-throughput screen for novel drug combinations targeting head and neck squamous carcinomas

January 2011

Dr Anne KiltieCRUK MRC Oxford Institute for Radiation Oncology
Collection and storage of bladder normal tissue and cancers (CASABLANCA)

Dr Anthony Kong, Department of Oncology
To investigate the resistance mechanisms of targeted therapies and to assess the HER2 dimerisation states of circulating tumour cells in non-HER2 over-expressed breast cancer in comparison to the HER2 over-expressed breast cancer cell lines and xenograft models

Dr Claire Edwards, Nuffield Department of Surgical Sciences
Adipokines in Prostate Cancer Bone Metastases

Dr Ester Hammond, Department of Oncology
Development and in vivo testing of bio-reductive replication inhibitors

Dr Kevin Myers, Department of Oncology
Biomarker development in Cancer Clinical Trials

Dr Coleman, Nuffield Department of Medicine
Cellular Studies of Cancer-associated ribosomal hydroxylases, MINA53 and NO66

Dr Leake, Department of Physics / Department of Biochemistry
Investigating cancer in living human cells using ultrasensitive single molecule optical microscopy

Professor Chetty, Nuffield Division of Clinical Laboratory Sciences
Quantitative imaging in molecular pathology

Dr Sharma, Department of Oncology
Pharmacological lethality with ionising radiation: Development of an innovative high-throughput assay for drug discovery

Dr Feller, Department of Oncology
Development of SH2 domains as probes for monitoring cancer drug activities in trials